What format is required for submitting sequence listings under the new rules?

Under the new Sequence Rules, patent applicants must submit sequence listings in a specific format. MPEP 2412.01 states that “an applicant is required to submit sequence data… in eXtensible Markup Language (XML) format.” This XML file must conform to the requirements specified in 37 CFR 1.831 – 1.834, which in turn reference particular paragraphs of…

Read More

What is the significance of WIPO Standard ST.26 in the MPEP’s definition of nucleotides?

The MPEP 2412.03(d) explicitly references WIPO Standard ST.26 in its definition of nucleotides: “‘Nucleotide’ includes any nucleotide, nucleotide analog, or modified nucleotide as defined in paragraphs 3(f) and 3(g) of WIPO Standard ST.26.” WIPO Standard ST.26 is an international standard for the presentation of nucleotide and amino acid sequence listings in patent applications. Its incorporation…

Read More

Where can I find the full text of WIPO Standard ST.26?

The full text of WIPO Standard ST.26 can be accessed through several official sources. MPEP 2412 provides direct links to the standard: 1. WIPO’s official website: www.wipo.int/export/sites/www/standards/en/pdf/03-26-01.pdf 2. USPTO’s Sequence Listing Resource Center: www.uspto.gov/patents/apply/sequence-listing-resource-center/learning-and-resources#standard26 Additionally, MPEP 2412 notes that “WIPO Standard ST.26 is incorporated by reference into the USPTO regulations by including new regulatory text…

Read More

What are the benefits of using WIPO Standard ST.26 for sequence listings?

WIPO Standard ST.26 offers several benefits for sequence listings in patent applications: International Compatibility: It allows for a single, internationally acceptable sequence listing format. Language Neutrality: The format is language-neutral, facilitating use across different countries and regions. Standardization: It uses specified International Nucleotide Sequence Database Collaboration (INSDC) identifiers, ensuring consistency across applications. Efficiency: A single…

Read More

What are the key differences between WIPO ST.25 and the new sequence rules for applications filed after July 1, 2022?

The MPEP 2420 indicates a significant change in the rules governing sequence disclosures in patent applications filed on or after July 1, 2022. The section states: “[Editor Note: This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR…

Read More

What are the WIPO ST.25 sample statements for sequence listings?

The MPEP provides sample language for statements required to support sequence rule submissions under WIPO ST.25. These statements are examples and not exhaustive. They primarily cover three areas: Asserting that the sequence information in the PDF or physical sheets is identical to the computer readable form Stating that amendments adding a sequence listing are supported…

Read More

When are WIPO ST.25 sample statements not applicable?

According to the MPEP, WIPO ST.25 sample statements are not applicable to certain patent applications. Specifically: “This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).” For applications filed on or after July 1, 2022, applicants should…

Read More

Where can I find a sample sequence listing under WIPO ST.25?

MPEP § 2431 mentions the availability of a sample sequence listing: “A sample ‘Sequence Listing’ is included below.” While the actual sample is not provided in the given excerpt, it’s typically included in the full MPEP section. For the most up-to-date and complete information, including the sample sequence listing, you should refer to the official…

Read More